Edwards Lifesciences Stock Price, News & Analysis (NYSE:EW)

$114.31 -1.09 (-0.94 %)
(As of 12/15/2017 10:58 AM ET)
Previous Close$115.40
Today's Range$113.85 - $116.07
52-Week Range$86.55 - $121.45
Volume1.95 million shs
Average Volume1.64 million shs
Market Capitalization$24.42 billion
P/E Ratio31.97
Dividend YieldN/A
Beta0.51

About Edwards Lifesciences (NYSE:EW)

Edwards Lifesciences logoEdwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. It is developing products, such as the Edwards SAPIEN 3 Ultra System and Edwards SAPIEN XT transcatheter heart valve, among others. Its Transcatheter Heart Valve Therapy and Surgical Heart Valve Therapy products are manufactured in the United States, Singapore and Switzerland. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic.

Receive EW News and Ratings via Email

Sign-up to receive the latest news and ratings for EW and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:EW
CUSIP28176E10
Phone949-250-2500

Debt

Debt-to-Equity Ratio0.33%
Current Ratio3.49%
Quick Ratio2.76%

Price-To-Earnings

Trailing P/E Ratio31.97
Forward P/E Ratio30.40
P/E Growth2.06

Sales & Book Value

Annual Sales$2.96 billion
Price / Sales8.16
Cash Flow$3.21 per share
Price / Cash35.65
Book Value$12.09 per share
Price / Book9.45

Profitability

Trailing EPS$3.44
Net Income$569.50 million
Net Margins22.47%
Return on Equity27.22%
Return on Assets15.67%

Miscellaneous

Employees11,100
Outstanding Shares211,620,000

Edwards Lifesciences (NYSE:EW) Frequently Asked Questions

What is Edwards Lifesciences' stock symbol?

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

When did Edwards Lifesciences' stock split? How did Edwards Lifesciences' stock split work?

Edwards Lifesciences shares split on the morning of Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly minted shares were payable to shareholders after the closing bell on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 200 shares after the split.

How will Edwards Lifesciences' stock buyback program work?

Edwards Lifesciences declared that its Board of Directors has authorized a share repurchase plan on Thursday, December 7th 2017, which authorizes the company to repurchase $1,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to purchase shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's board of directors believes its shares are undervalued.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Corporation (NYSE:EW) released its quarterly earnings data on Tuesday, October, 24th. The medical research company reported $0.84 EPS for the quarter, missing the Zacks' consensus estimate of $0.86 by $0.02. The medical research company had revenue of $821.50 million for the quarter, compared to analyst estimates of $833.85 million. Edwards Lifesciences had a net margin of 22.47% and a return on equity of 27.22%. The firm's revenue for the quarter was up 11.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.68 EPS. View Edwards Lifesciences' Earnings History.

When will Edwards Lifesciences make its next earnings announcement?

Edwards Lifesciences is scheduled to release their next quarterly earnings announcement on Wednesday, February, 7th 2018. View Earnings Estimates for Edwards Lifesciences.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences updated its FY18 earnings guidance on Thursday, December, 7th. The company provided earnings per share (EPS) guidance of $4.10-4.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.15. The company issued revenue guidance of $3.5-3.9 billion, compared to the consensus revenue estimate of $3.71 billion.Edwards Lifesciences also updated its FY17 guidance to $3.65-3.85 EPS.

Where is Edwards Lifesciences' stock going? Where will Edwards Lifesciences' stock price be in 2017?

19 analysts have issued 12 month price targets for Edwards Lifesciences' shares. Their predictions range from $105.00 to $150.00. On average, they expect Edwards Lifesciences' share price to reach $126.31 in the next twelve months. View Analyst Ratings for Edwards Lifesciences.

What are Wall Street analysts saying about Edwards Lifesciences stock?

Here are some recent quotes from research analysts about Edwards Lifesciences stock:

  • 1. According to Zacks Investment Research, "Over the last six months, Edwards Lifesciences has outperformed the broader industry. Edwards Lifesciences’ second-quarter 2017 performance was quite promising . Moreover, the raised guidance for 2017 hints at brighter prospects. In fact, the guidance raise was backed by a strong performance by all of the company’s three product lines.   We believe that the recent FDA approvals for several products including SAPIEN 3 THV for valve-in-valve procedures and INSPIRIS RESILIA aortic valve have been boosting investors’ confidence on the stock. However, higher operating expenses raise concerns. The stock’s valuation is also stretched on huge investments in the launch and promotion of products. Stiff competition, currency headwind and reimbursement issues are other challenges." (9/26/2017)
  • 2. Cowen Inc analysts commented, "After hosting meetings with management last week, attending ACC, and reviewing early 1Q'17 MedMine hospital purchasing data, we remain bullish on Edwards' long term growth prospects. We are optimistic that additional layers of growth will be provided by low risk, asymptomatic and moderate AS indications along with EW's mitral and tricuspid platforms. Reiterate Outperform." (3/28/2017)
  • 3. Evercore ISI analysts commented, "With lowered investor expectations, we believe EW shares are poised for a 'catch-up' trade and offers asymmetric risk-reward at current levels. As a result, we are upgrading shares to a Buy, and raising our PT to $110, which offers ~15% upside from current levels." (3/27/2017)

Are investors shorting Edwards Lifesciences?

Edwards Lifesciences saw a increase in short interest in November. As of November 30th, there was short interest totalling 3,268,951 shares, an increase of 46.8% from the November 15th total of 2,227,211 shares. Based on an average daily trading volume, of 1,519,258 shares, the days-to-cover ratio is presently 2.2 days. Currently, 1.6% of the company's stock are short sold.

Who are some of Edwards Lifesciences' key competitors?

Who are Edwards Lifesciences' key executives?

Edwards Lifesciences' management team includes the folowing people:

  • Michael A. Mussallem, Chairman of the Board, Chief Executive Officer (Age 64)
  • Scott B. Ullem, Chief Financial Officer, Corporate Vice President (Age 50)
  • Donald E. Bobo Jr., Corporate Vice President - Heart Valve Therapy (Age 55)
  • Catherine M. Szyman, Corporate Vice President- Critical Care (Age 50)
  • Patrick Bruno Verguet, Corporate Vice President- Europe, Middle East and Africa (Age 59)
  • Huimin Wang M.D., Corporate Vice President- Japan, Asia and Pacific (Age 60)
  • Larry L. Wood, Corporate Vice President - Transcatheter Heart Valve Therapy (Age 51)
  • Bernard J. Zovighian, Corporate Vice President -Surgical Heart Valve Therapy (Age 49)
  • Kieran T. Gallahue, Independent Director (Age 53)
  • Leslie Stone Heisz, Independent Director (Age 56)

Who owns Edwards Lifesciences stock?

Edwards Lifesciences' stock is owned by many different of retail and institutional investors. Top institutional investors include Bank of New York Mellon Corp (2.46%), Ameriprise Financial Inc. (2.00%), Brown Advisory Inc. (1.79%), Wells Fargo & Company MN (1.20%), American Century Companies Inc. (1.05%) and Disciplined Growth Investors Inc. MN (0.99%). Company insiders that own Edwards Lifesciences stock include Barbara J Mcneil, Bernard J Zovighian, Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Dylan Sidoo, Huimin Wang, John T Cardis, Kieran Gallahue, Larry L Wood, Michael A Mussallem, Nick Demare, Patrick B Verguet, Robert WA Sellers, Schack Wesley W Von and Steven R Loranger. View Institutional Ownership Trends for Edwards Lifesciences.

Who sold Edwards Lifesciences stock? Who is selling Edwards Lifesciences stock?

Edwards Lifesciences' stock was sold by a variety of institutional investors in the last quarter, including Brown Advisory Inc., Egerton Capital UK LLP, Orbimed Advisors LLC, Ameriprise Financial Inc., State of Wisconsin Investment Board, Bank of New York Mellon Corp, Rockefeller Financial Services Inc. and Montag & Caldwell LLC. Company insiders that have sold Edwards Lifesciences company stock in the last year include Bernard J Zovighian, Catherine M Szyman, Donald E Bobo, Jr, Larry L Wood, Michael A Mussallem, Patrick B Verguet and Schack Wesley W Von. View Insider Buying and Selling for Edwards Lifesciences.

Who bought Edwards Lifesciences stock? Who is buying Edwards Lifesciences stock?

Edwards Lifesciences' stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Old Mutual Global Investors UK Ltd., Wells Fargo & Company MN, Ardevora Asset Management LLP, Korea Investment CORP, First Trust Advisors LP, Artisan Partners Limited Partnership and American Century Companies Inc.. Company insiders that have bought Edwards Lifesciences stock in the last two years include Catherine M Szyman, Dylan Sidoo, Kieran Gallahue, Nick Demare and Steven R Loranger. View Insider Buying and Selling for Edwards Lifesciences.

How do I buy Edwards Lifesciences stock?

Shares of Edwards Lifesciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Edwards Lifesciences' stock price today?

One share of Edwards Lifesciences stock can currently be purchased for approximately $114.31.

How big of a company is Edwards Lifesciences?

Edwards Lifesciences has a market capitalization of $24.42 billion and generates $2.96 billion in revenue each year. The medical research company earns $569.50 million in net income (profit) each year or $3.44 on an earnings per share basis. Edwards Lifesciences employs 11,100 workers across the globe.

How can I contact Edwards Lifesciences?

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]


MarketBeat Community Rating for Edwards Lifesciences (EW)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  811 (Vote Outperform)
Underperform Votes:  578 (Vote Underperform)
Total Votes:  1,389
MarketBeat's community ratings are surveys of what our community members think about Edwards Lifesciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Edwards Lifesciences (NYSE:EW) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.752.762.77
Ratings Breakdown: 1 Sell Rating(s)
5 Hold Rating(s)
17 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
17 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
18 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
19 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $124.00$123.68$119.09$116.42
Price Target Upside: 5.06% upside19.70% upside5.10% upside1.59% upside

Edwards Lifesciences (NYSE:EW) Consensus Price Target History

Price Target History for Edwards Lifesciences (NYSE:EW)

Edwards Lifesciences (NYSE:EW) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/10/2017CowenSet Price TargetBuy$135.00LowView Rating Details
12/8/2017BMO Capital MarketsReiterated RatingBuy$137.00LowView Rating Details
11/29/2017Canaccord GenuityReiterated RatingBuy$137.00LowView Rating Details
10/26/2017Deutsche BankLower Price TargetHold$122.00 -> $115.00N/AView Rating Details
10/26/2017Morgan StanleyLower Price TargetOverweight$133.00 -> $120.00N/AView Rating Details
10/25/2017BarclaysLower Price TargetEqual Weight$120.00 -> $118.00N/AView Rating Details
10/25/2017SunTrust BanksSet Price TargetBuy$124.00N/AView Rating Details
9/1/2017Royal Bank of CanadaReiterated RatingBuy$130.00N/AView Rating Details
8/28/2017William BlairReiterated RatingOutperform -> OutperformLowView Rating Details
7/27/2017Stifel NicolausReiterated RatingBuy -> Buy$118.00 -> $130.00HighView Rating Details
7/27/2017Bank of AmericaBoost Price TargetPositive -> Buy$140.00 -> $150.00HighView Rating Details
7/27/2017Jefferies GroupBoost Price TargetBuy$115.00 -> $132.00HighView Rating Details
5/16/2017Goldman Sachs GroupInitiated CoverageConviction-Buy$138.00LowView Rating Details
3/27/2017Evercore ISIUpgradeIn-Line -> Outperform$98.50 -> $110.00LowView Rating Details
3/20/2017Northland SecuritiesSet Price TargetBuy$105.00LowView Rating Details
2/8/2017Credit Suisse GroupSet Price TargetBuy$120.00N/AView Rating Details
2/2/2017Leerink SwannDowngradeOutperform -> Market PerformN/AView Rating Details
2/2/2017BTIG ResearchDowngradeBuy -> NeutralN/AView Rating Details
1/3/2017GuggenheimUpgradeNeutral -> Buy$120.00N/AView Rating Details
12/10/2016JMP SecuritiesReiterated RatingEqual Weight$130.00N/AView Rating Details
12/1/2016J P Morgan Chase & CoSet Price TargetBuy$120.00N/AView Rating Details
9/11/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
7/27/2016CitigroupBoost Price TargetSell$86.00 -> $94.00N/AView Rating Details
6/21/2016Piper Jaffray CompaniesReiterated RatingOverweight$123.00N/AView Rating Details
3/17/2016NomuraInitiated CoverageBuy$101.00N/AView Rating Details
1/4/2016Sterne Agee CRTBoost Price TargetBuy$90.00 -> $92.00N/AView Rating Details
(Data available from 12/15/2015 forward)

Earnings

Edwards Lifesciences (NYSE:EW) Earnings History and Estimates Chart

Earnings by Quarter for Edwards Lifesciences (NYSE:EW)

Edwards Lifesciences (NYSE EW) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/30/2018$0.90N/AView Earnings Details
10/24/2017Q3 2017$0.86$0.84$833.85 million$821.50 millionViewN/AView Earnings Details
7/26/2017Q2 2017$0.88$1.08$839.16 million$842.00 millionViewN/AView Earnings Details
4/25/2017Q1 2017$0.82$0.94$776.51 million$883.50 millionViewN/AView Earnings Details
2/1/2017Q416$0.72$0.75$760.85 million$767.70 millionViewN/AView Earnings Details
10/25/2016Q316$0.68$0.68$749.14 million$739.40 millionViewN/AView Earnings Details
7/26/2016Q216$0.70$0.76$724.26 million$759.30 millionViewN/AView Earnings Details
4/26/2016Q116$0.66$0.71$664.53 million$697.30 millionViewN/AView Earnings Details
2/2/2016Q415$0.62$0.63$647.44 million$671.10 millionViewN/AView Earnings Details
10/26/2015Q315$0.98$1.07$598.29 million$615.00 millionViewN/AView Earnings Details
7/28/2015Q215$1.05$1.13$604.97 million$616.80 millionViewN/AView Earnings Details
4/23/2015Q115$1.04$1.12$585.16 million$590.30 millionViewN/AView Earnings Details
2/3/2015Q414$0.95$1.06$610.50 million$618.00 millionViewListenView Earnings Details
10/23/2014Q314$0.72$0.80$546.10 million$607.40 millionViewListenView Earnings Details
7/29/2014Q214$0.77$0.88$545.10 million$547.00 millionViewListenView Earnings Details
4/24/2014Q114$0.69$0.76$523.10 million$522.40 millionViewListenView Earnings Details
2/3/2014Q413$0.82$0.91$533.82 million$536.00 millionViewN/AView Earnings Details
10/28/2013Q313$0.66$0.68$490.96 million$496.00 millionViewN/AView Earnings Details
7/25/2013Q2 2013$0.76$0.82$514.59 million$517.20 millionViewN/AView Earnings Details
4/23/2013Q1 2013$0.76$0.72$518.69 million$496.70 millionViewN/AView Earnings Details
2/4/2013Q4 2012$0.77$0.77$499.46 million$510.50 millionViewN/AView Earnings Details
10/19/2012$0.56$0.58ViewN/AView Earnings Details
7/24/2012$0.66$0.67ViewN/AView Earnings Details
2/2/2012$0.59$0.62ViewN/AView Earnings Details
10/19/2011$0.39$0.38ViewN/AView Earnings Details
7/21/2011$0.50$0.49ViewN/AView Earnings Details
4/20/2011$0.42$0.51ViewN/AView Earnings Details
2/2/2011$0.53$0.55ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Edwards Lifesciences (NYSE:EW) Earnings Estimates

2017 EPS Consensus Estimate: $3.45
2018 EPS Consensus Estimate: $4.16
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174$0.82$0.85$0.84
Q2 20174$0.87$0.89$0.88
Q3 20174$0.79$0.86$0.84
Q4 20174$0.89$0.91$0.90
Q1 20184$0.98$1.09$1.02
Q2 20184$1.06$1.13$1.10
Q3 20184$0.93$1.03$0.99
Q4 20184$0.97$1.09$1.05
Q1 20191$1.11$1.11$1.11
Q2 20191$1.23$1.23$1.23
Q3 20191$1.14$1.14$1.14
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Edwards Lifesciences (NYSE:EW)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Edwards Lifesciences (NYSE EW) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.13%
Institutional Ownership Percentage: 81.82%
Insider Trades by Quarter for Edwards Lifesciences (NYSE:EW)
Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Edwards Lifesciences (NYSE EW) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/29/2017Donald E. Bobo, Jr.VPSell5,300$116.45$617,185.00View SEC Filing  
11/20/2017Michael A. MussallemCEOSell32,900$106.86$3,515,694.00View SEC Filing  
11/15/2017Larry L. WoodVPSell18,960$104.76$1,986,249.60View SEC Filing  
11/9/2017Schack Wesley W VonDirectorSell1,000$104.15$104,150.00View SEC Filing  
10/30/2017Donald E. Bobo, Jr.VPSell5,300$101.12$535,936.00View SEC Filing  
10/30/2017Michael A. MussallemCEOSell32,900$100.93$3,320,597.00View SEC Filing  
10/16/2017Larry L WoodVPSell18,960$108.54$2,057,918.40View SEC Filing  
9/29/2017Donald E. Bobo, Jr.VPSell5,300$108.86$576,958.00View SEC Filing  
9/15/2017Larry L. WoodVPSell18,960$112.58$2,134,516.80View SEC Filing  
9/7/2017Michael A. MussallemCEOSell32,900$112.45$3,699,605.00View SEC Filing  
8/30/2017Larry L. WoodVPSell18,960$111.81$2,119,917.60View SEC Filing  
8/29/2017Donald E. Bobo, Jr.VPSell5,300$112.15$594,395.00View SEC Filing  
8/9/2017Michael A. MussallemCEOSell32,900$115.99$3,816,071.00View SEC Filing  
8/4/2017Donald E. Bobo, Jr.VPSell25,000$116.00$2,900,000.00View SEC Filing  
7/31/2017Catherine M. SzymanVPSell4,681$115.78$541,966.18View SEC Filing  
7/31/2017Michael A. MussallemCEOSell32,900$114.80$3,776,920.00View SEC Filing  
7/28/2017Donald E. Bobo, Jr.VPSell5,300$114.68$607,804.00View SEC Filing  
6/29/2017Donald E. Bobo, Jr.VPSell5,600$117.15$656,040.00View SEC Filing  
6/7/2017Michael A. MussallemCEOSell32,900$118.05$3,883,845.00View SEC Filing  
5/31/2017Patrick B. VerguetVPSell10,000$114.88$1,148,800.00View SEC Filing  
5/19/2017Dylan SidooDirectorBuy25,000$0.11$2,750.00
5/19/2017Patrick B. VerguetVPSell22,631$113.16$2,560,923.96View SEC Filing  
5/15/2017Patrick B. VerguetVPSell11,500$111.64$1,283,860.00View SEC Filing  
5/8/2017Donald E. Bobo, Jr.VPSell19,100$110.34$2,107,494.00View SEC Filing  
5/4/2017Donald E. Bobo, Jr.VPSell34,120$109.98$3,752,517.60View SEC Filing  
5/3/2017Michael A. MussallemCEOSell49,100$109.71$5,386,761.00View SEC Filing  
4/28/2017Michael A. MussallemCEOSell49,100$109.78$5,390,198.00View SEC Filing  
4/27/2017Bernard J. ZovighianVPSell18,050$109.21$1,971,240.50View SEC Filing  
4/5/2017Donald E. Bobo, Jr.VPSell13,720$93.58$1,283,917.60View SEC Filing  
3/30/2017Patrick B. VerguetVPSell24,000$93.90$2,253,600.00View SEC Filing  
3/6/2017Donald E. Bobo, Jr.VPSell13,720$90.01$1,234,937.20View SEC Filing  
2/16/2017Michael A. MussallemCEOSell49,100$89.63$4,400,833.00View SEC Filing  
2/3/2017Kieran GallahueDirectorBuy3,000$90.10$270,300.00View SEC Filing  
1/13/2017Michael A. MussallemCEOSell49,100$97.08$4,766,628.00View SEC Filing  
1/12/2017Donald E. Bobo, Jr.VPSell13,720$97.47$1,337,288.40View SEC Filing  
1/12/2017Dylan SidooDirectorBuy30,000$0.13$3,900.00
1/11/2017Dylan SidooDirectorBuy20,000$0.13$2,600.00
12/19/2016Michael A. MussallemCEOSell49,100$91.96$4,515,236.00View SEC Filing  
12/5/2016Huimin WangVPSell13,650$83.53$1,140,184.50View SEC Filing  
12/1/2016Larry L. WoodVPSell13,258$81.85$1,085,167.30View SEC Filing  
11/30/2016Catherine M. SzymanVPBuy12,870$83.43$1,073,744.10View SEC Filing  
11/29/2016Kieran GallahueDirectorBuy3,000$84.63$253,890.00View SEC Filing  
11/22/2016Michael A. MussallemCEOSell49,100$84.67$4,157,297.00View SEC Filing  
11/7/2016Huimin WangVPSell13,650$91.29$1,246,108.50View SEC Filing  
11/2/2016Donald E. Bobo, Jr.VPSell15,000$90.13$1,351,950.00View SEC Filing  
11/1/2016Larry L. WoodVPSell13,257$93.27$1,236,480.39View SEC Filing  
10/27/2016Michael A. MussallemCEOSell49,100$92.77$4,555,007.00View SEC Filing  
10/5/2016Huimin WangVPSell13,650$120.04$1,638,546.00View SEC Filing  
10/3/2016Larry L. WoodVPSell13,257$119.27$1,581,162.39View SEC Filing  
9/6/2016Huimin WangVPSell13,650$115.72$1,579,578.00View SEC Filing  
9/2/2016Donald E. Bobo, Jr.VPSell18,000$115.78$2,084,040.00View SEC Filing  
8/26/2016Patrick B. VerguetVPSell5,000$114.88$574,400.00View SEC Filing  
8/24/2016Patrick B. VerguetVPSell5,000$116.81$584,050.00View SEC Filing  
8/23/2016Patrick B. VerguetVPSell10,092$117.53$1,186,112.76View SEC Filing  
8/11/2016Michael A. MussallemCEOSell49,100$114.01$5,597,891.00View SEC Filing  
8/10/2016John T. CardisDirectorSell5,000$113.21$566,050.00View SEC Filing  
8/9/2016Patrick B. VerguetVPSell10,000$113.48$1,134,800.00View SEC Filing  
8/5/2016Huimin WangVPSell13,650$113.03$1,542,859.50View SEC Filing  
8/1/2016Larry L. WoodVPSell13,257$114.24$1,514,479.68View SEC Filing  
8/1/2016Schack Wesley W. VonDirectorSell6,000$113.98$683,880.00View SEC Filing  
7/29/2016Robert W.A. SellersVPSell10,000$114.33$1,143,300.00View SEC Filing  
7/28/2016Michael A. MussallemCEOSell49,100$113.31$5,563,521.00View SEC Filing  
7/5/2016Huimin WangVPSell13,650$98.44$1,343,706.00View SEC Filing  
7/1/2016Larry L. WoodVPSell13,257$98.79$1,309,659.03View SEC Filing  
6/8/2016Michael A MussallemCEOSell49,100$102.75$5,045,025.00View SEC Filing  
6/6/2016Huimin WangVPSell13,650$101.34$1,383,291.00View SEC Filing  
6/3/2016Larry L WoodVPSell13,257$101.38$1,343,994.66View SEC Filing  
5/31/2016Donald E Bobo JrVPSell18,000$99.04$1,782,720.00View SEC Filing  
5/24/2016Steven R LorangerDirectorBuy5,000$101.07$505,350.00View SEC Filing  
5/18/2016Patrick B VerguetVPSell13,000$102.75$1,335,750.00View SEC Filing  
5/17/2016Patrick B VerguetVPSell5,000$105.00$525,000.00View SEC Filing  
5/16/2016Patrick B VerguetVPSell3,000$104.62$313,860.00View SEC Filing  
5/5/2016Huimin WangVPSell13,650$103.36$1,410,864.00View SEC Filing  
5/5/2016Michael A MussallemCEOSell59,000$104.12$6,143,080.00View SEC Filing  
5/2/2016Patrick B VerguetVPSell7,000$106.86$748,020.00View SEC Filing  
4/29/2016Michael A MussallemCEOSell59,000$106.13$6,261,670.00View SEC Filing  
4/5/2016Huimin WangVPSell13,650$103.97$1,419,190.50View SEC Filing  
3/17/2016Michael A MussallemCEOSell59,000$84.39$4,979,010.00View SEC Filing  
3/7/2016Huimin WangVPSell13,650$87.17$1,189,870.50View SEC Filing  
2/18/2016Michael A. MussallemCEOSell59,000$86.94$5,129,460.00View SEC Filing  
2/18/2016Patrick B. VerguetVPSell5,000$87.00$435,000.00View SEC Filing  
2/16/2016Patrick B. VerguetVPSell8,000$81.58$652,640.00View SEC Filing  
2/5/2016Huimin WangVPSell13,650$83.46$1,139,229.00View SEC Filing  
2/4/2016Barbara J. McneilDirectorSell4,000$83.29$333,160.00View SEC Filing  
1/21/2016Patrick B. VerguetVPSell8,000$77.00$616,000.00View SEC Filing  
1/6/2016Nick DemareDirectorBuy15,000$0.08$1,200.00
1/5/2016Huimin WangVPSell13,650$78.50$1,071,525.00View SEC Filing  
1/5/2016Michael A. MussallemCEOSell59,000$79.82$4,709,380.00View SEC Filing  
12/17/2015Michael A. MussallemCEOSell59,000$81.85$4,829,150.00View SEC Filing  
12/15/2015Patrick B. VerguetVPSell8,000$80.87$646,960.00View SEC Filing  
12/4/2015Huimin WangVPSell6,880$157.96$1,086,764.80View SEC Filing  
11/27/2015Patrick B. VerguetVPSell7,500$164.50$1,233,750.00View SEC Filing  
11/23/2015Robert W.A. SellersVPSell19,200$157.13$3,016,896.00View SEC Filing  
11/17/2015Patrick B. VerguetVPSell4,000$154.50$618,000.00View SEC Filing  
11/5/2015Huimin WangVPSell6,920$156.01$1,079,589.20View SEC Filing  
11/3/2015Patrick B. VerguetVPSell4,338$158.48$687,486.24View SEC Filing  
10/30/2015Patrick B. VerguetVPSell22,000$155.09$3,411,980.00View SEC Filing  
10/29/2015Michael A MussallemCEOSell29,500$154.59$4,560,405.00View SEC Filing  
10/5/2015Huimin WangVPSell6,920$154.30$1,067,756.00View SEC Filing  
10/2/2015Patrick B. VerguetVPSell4,000$154.00$616,000.00View SEC Filing  
10/1/2015Larry L. WoodVPSell7,680$141.52$1,086,873.60View SEC Filing  
9/21/2015Michael A. MussallemCEOSell29,500$142.49$4,203,455.00View SEC Filing  
9/4/2015Huimin WangVPSell6,920$135.19$935,514.80View SEC Filing  
9/1/2015Larry L. WoodVPSell7,680$137.50$1,056,000.00View SEC Filing  
8/24/2015Michael A. MussallemCEOSell29,500$135.25$3,989,875.00View SEC Filing  
8/13/2015West Petroleum Corp. EastInsiderBuy25,000$0.12$2,875.00
7/6/2015Huimin WangVPSell6,920$143.95$996,134.00View SEC Filing  
7/1/2015Larry L WoodVPSell7,680$143.51$1,102,156.80View SEC Filing  
6/24/2015Michael A MussallemCEOSell29,500$143.71$4,239,445.00View SEC Filing  
6/5/2015Huimin WangVPSell6,920$131.39$909,218.80View SEC Filing  
6/1/2015Larry L WoodVPSell7,680$130.47$1,002,009.60View SEC Filing  
5/29/2015Patrick B VerguetVPSell9,662$131.18$1,267,461.16View SEC Filing  
5/21/2015Barbara J McneilDirectorSell2,000$132.59$265,180.00View SEC Filing  
5/19/2015Robert Marc BustinDirectorSell10,000$0.18$1,750.00
5/1/2015Larry L WoodVPSell7,680$127.12$976,281.60View SEC Filing  
4/30/2015Michael A MussallemCEOSell29,500$128.99$3,805,205.00View SEC Filing  
4/6/2015Huimin WangVPSell6,920$140.24$970,460.80View SEC Filing  
4/1/2015Larry L WoodVPSell7,680$142.06$1,091,020.80View SEC Filing  
3/31/2015Robert Marc BustinDirectorBuy15,000$0.15$2,250.00
3/26/2015Michael A MussallemCEOSell29,500$140.10$4,132,950.00View SEC Filing  
3/2/2015Larry L WoodVPSell7,680$132.62$1,018,521.60View SEC Filing  
2/6/2015Huimin WangVPSell6,920$134.79$932,746.80View SEC Filing  
1/5/2015Huimin WangVPSell6,920$126.60$876,072.00View SEC Filing  
1/5/2015Michael A MussallemCEOSell29,500$128.20$3,781,900.00View SEC Filing  
12/22/2014Michael A MussallemCEOSell29,500$133.01$3,923,795.00View SEC Filing  
11/24/2014Michael A MussallemCEOSell29,500$124.25$3,665,375.00View SEC Filing  
11/13/2014Robert W.A. SellersVPSell3,400$124.27$422,518.00View SEC Filing  
11/10/2014Patrick B VerguetVPSell5,000$123.70$618,500.00View SEC Filing  
11/7/2014Schack Wesley W VonDirectorSell3,655$123.00$449,565.00View SEC Filing  
11/5/2014Huimin WangVPSell5,600$120.26$673,456.00View SEC Filing  
10/28/2014Barbara J McneilDirectorSell1,000$117.94$117,940.00View SEC Filing  
10/28/2014Michael A MussallemCEOSell29,500$117.06$3,453,270.00View SEC Filing  
10/28/2014Patrick B VerguetVPSell15,000$117.33$1,759,950.00View SEC Filing  
10/28/2014West Petroleum Corp. EastInsiderBuy15,000$0.12$1,800.00
10/27/2014Patrick B VerguetVPSell10,000$117.00$1,170,000.00View SEC Filing  
10/27/2014West Petroleum Corp. EastInsiderBuy20,000$0.13$2,600.00
10/24/2014Donald E Bobo JrVPSell30,000$114.25$3,427,500.00View SEC Filing  
10/24/2014West Petroleum Corp. EastInsiderBuy35,000$0.14$4,725.00
10/23/2014West Petroleum Corp. EastInsiderBuy40,000$0.15$5,800.00
10/6/2014Huimin WangVPSell5,600$107.00$599,200.00View SEC Filing  
10/3/2014Donald E Bobo JrVPSell25,000$105.00$2,625,000.00View SEC Filing  
9/29/2014Michael A MussallemCEOSell29,500$102.71$3,029,945.00View SEC Filing  
9/10/2014Donald E Bobo JrVPSell25,000$100.00$2,500,000.00View SEC Filing  
9/5/2014Huimin WangVPSell5,600$98.29$550,424.00View SEC Filing  
8/27/2014Carlyn D SolomonVPSell85,200$97.85$8,336,820.00View SEC Filing  
8/27/2014Michael A MussallemCEOSell29,500$98.14$2,895,130.00View SEC Filing  
8/18/2014John T CardisDirectorSell6,000$97.92$587,520.00View SEC Filing  
8/18/2014Larry L WoodVPSell63,752$97.85$6,238,133.20View SEC Filing  
8/13/2014Patrick B VerguetVPSell7,800$95.50$744,900.00View SEC Filing  
8/5/2014Patrick B VerguetVPSell15,000$94.05$1,410,750.00View SEC Filing  
8/4/2014Patrick B VerguetVPSell5,000$93.00$465,000.00View SEC Filing  
8/1/2014Patrick B VerguetVPSell5,000$92.00$460,000.00View SEC Filing  
7/31/2014Michael A MussallemCEOSell29,500$91.98$2,713,410.00View SEC Filing  
7/31/2014Robert Alexander IngramDirectorSell12,500$90.26$1,128,250.00View SEC Filing  
7/31/2014Robert W.A. SellersVPSell8,850$91.47$809,509.50View SEC Filing  
7/30/2014Donald E Bobo JrVPSell23,270$92.00$2,140,840.00View SEC Filing  
7/7/2014Huimin WangVPSell5,600$87.79$491,624.00View SEC Filing  
6/27/2014Donald E Bobo JrVPSell25,000$87.00$2,175,000.00View SEC Filing  
6/24/2014Michael A MussallemCEOSell29,500$85.38$2,518,710.00View SEC Filing  
6/5/2014Huimin WangVPSell5,600$80.73$452,088.00View SEC Filing  
5/30/2014Barbara J McneilDirectorSell1,200$81.20$97,440.00View SEC Filing  
5/28/2014Michael A MussallemCEOSell29,500$79.33$2,340,235.00View SEC Filing  
4/14/2014Donald Bobo, Jr.VPSell25,000$82.00$2,050,000.00View SEC Filing  
4/10/2014Michael MussallemCEOSell29,500$74.71$2,203,945.00View SEC Filing  
4/7/2014Huimin WangVPSell5,600$74.03$414,568.00View SEC Filing  
3/24/2014Michael BowlinDirectorSell1,093$72.33$79,056.69View SEC Filing  
3/6/2014Robert W.A. SellersVPSell1,650$72.88$120,252.00View SEC Filing  
2/6/2014Michael MussallemCEOSell29,500$66.92$1,974,140.00View SEC Filing  
1/27/2014Michael BowlinDirectorSell1,092$68.65$74,965.80View SEC Filing  
1/9/2014Michael MussallemCEOSell29,500$67.04$1,977,680.00View SEC Filing  
1/6/2014Huimin WangVPSell5,600$67.14$375,984.00View SEC Filing  
12/11/2013Patrick VerguetVPSell10,000$62.34$623,400.00View SEC Filing  
12/5/2013Huimin WangVPSell4,650$64.65$300,622.50View SEC Filing  
12/4/2013Michael MussallemCEOSell29,500$64.90$1,914,550.00View SEC Filing  
10/9/2013Michael MussallemCEOSell29,500$72.63$2,142,585.00View SEC Filing  
10/4/2013Huimin WangVPSell4,850$72.19$350,121.50View SEC Filing  
9/12/2013Michael MussallemCEOSell29,500$71.82$2,118,690.00View SEC Filing  
9/5/2013Huimin WangVPSell4,850$71.24$345,514.00View SEC Filing  
8/8/2013Michael MussallemCEOSell29,500$72.28$2,132,260.00View SEC Filing  
8/5/2013Huimin WangVPSell4,850$72.30$350,655.00View SEC Filing  
8/1/2013Patrick VerguetVPSell20,000$73.15$1,463,000.00View SEC Filing  
7/10/2013Michael A MussallemCEOSell29,500$65.60$1,935,200.00View SEC Filing  
7/5/2013Huimin WangVPSell4,850$65.69$318,596.50View SEC Filing  
6/6/2013Michael A MussallemCEOSell29,500$66.25$1,954,375.00View SEC Filing  
6/5/2013Huimin WangVPSell4,850$65.11$315,783.50View SEC Filing  
5/13/2013Paul C RedmondVPSell5,000$67.35$336,750.00View SEC Filing  
5/8/2013Michael A MussallemCEOSell29,200$64.24$1,875,808.00View SEC Filing  
5/7/2013Thomas M AbateCFOSell15,000$63.75$956,250.00View SEC Filing  
5/3/2013Schack Wesley W VonDirectorBuy1,000$64.00$64,000.00View SEC Filing  
5/1/2013David E I PyottDirectorBuy3,000$62.95$188,850.00View SEC Filing  
5/1/2013John H Kehl JrVPSell12,500$62.72$784,000.00View SEC Filing  
4/26/2013Schack Wesley W VonDirectorBuy2,000$64.95$129,900.00View SEC Filing  
4/10/2013Michael A MussallemCEOSell35,000$83.37$2,917,950.00View SEC Filing  
3/13/2013John H Kehl JrVPSell12,500$87.75$1,096,875.00View SEC Filing  
10/5/2012Huimin WangVPSell6,250$109.88$686,750.00View SEC Filing  
10/4/2012Donald E Bobo JrVPSell11,530$110.14$1,269,914.20View SEC Filing  
8/9/2012Michael A MussallemCEOSell35,000$98.69$3,454,150.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Edwards Lifesciences (NYSE EW) News Headlines

Source:
DateHeadline
Kaman Corporation (KAMN) Ex-Dividend Date Scheduled for December 18, 2017 - NasdaqKaman Corporation (KAMN) Ex-Dividend Date Scheduled for December 18, 2017 - Nasdaq
www.nasdaq.com - December 15 at 10:16 AM
Zacks: Analysts Expect Edwards Lifesciences Corporation (EW) Will Announce Quarterly Sales of $862.69 MillionZacks: Analysts Expect Edwards Lifesciences Corporation (EW) Will Announce Quarterly Sales of $862.69 Million
www.americanbankingnews.com - December 13 at 11:36 AM
Edwards Lifesciences (EW) Ranking Raised to Buy on Robust Earnings GrowthEdwards Lifesciences (EW) Ranking Raised to Buy on Robust Earnings Growth
investorplace.com - December 12 at 12:35 PM
Edwards Lifesciences Corporation (EW) Given Average Rating of "Buy" by AnalystsEdwards Lifesciences Corporation (EW) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - December 11 at 10:22 PM
Edwards Lifesciences (EW) Given a $135.00 Price Target at CowenEdwards Lifesciences (EW) Given a $135.00 Price Target at Cowen
www.americanbankingnews.com - December 11 at 3:40 PM
Jefferies Group Research Analysts Boost Earnings Estimates for Edwards Lifesciences Corporation (EW)Jefferies Group Research Analysts Boost Earnings Estimates for Edwards Lifesciences Corporation (EW)
www.americanbankingnews.com - December 11 at 5:38 AM
Edwards Lifesciences Corporation to Post Q2 2018 Earnings of $1.12 Per Share, Leerink Swann Forecasts (EW)Edwards Lifesciences Corporation to Post Q2 2018 Earnings of $1.12 Per Share, Leerink Swann Forecasts (EW)
www.americanbankingnews.com - December 11 at 5:38 AM
Edwards Lifesciences Corporation to Post Q4 2017 Earnings of $0.89 Per Share, William Blair Forecasts (EW)Edwards Lifesciences Corporation to Post Q4 2017 Earnings of $0.89 Per Share, William Blair Forecasts (EW)
www.americanbankingnews.com - December 11 at 3:08 AM
BMO Capital Markets Reaffirms "Buy" Rating for Edwards Lifesciences (EW)BMO Capital Markets Reaffirms "Buy" Rating for Edwards Lifesciences (EW)
www.americanbankingnews.com - December 9 at 12:08 PM
Edwards Lifesciences (EW) to Acquire Harpoon Medical for $100M, Plus Up to $150M in Milestone PaymentsEdwards Lifesciences (EW) to Acquire Harpoon Medical for $100M, Plus Up to $150M in Milestone Payments
www.streetinsider.com - December 7 at 5:28 PM
Edwards Lifesciences Outlines Growth Strategy At Annual Investor ConferenceEdwards Lifesciences Outlines Growth Strategy At Annual Investor Conference
finance.yahoo.com - December 7 at 5:28 PM
Edwards Lifesciences Board Approves New $1 Billion Share Repurchase ProgramEdwards Lifesciences' Board Approves New $1 Billion Share Repurchase Program
finance.yahoo.com - December 7 at 5:28 PM
Edwards Lifesciences sets $1 billion stock buyback program, gives 2018 guidanceEdwards Lifesciences sets $1 billion stock buyback program, gives 2018 guidance
finance.yahoo.com - December 7 at 5:28 PM
[$$] Harpoon Medical Acquired by Edwards Lifesciences[$$] Harpoon Medical Acquired by Edwards Lifesciences
finance.yahoo.com - December 7 at 5:28 PM
Edwards Lifesciences (EW) Issues FY18 Earnings GuidanceEdwards Lifesciences (EW) Issues FY18 Earnings Guidance
www.americanbankingnews.com - December 7 at 5:08 PM
Edwards Lifesciences (EW) Releases FY17 Earnings GuidanceEdwards Lifesciences (EW) Releases FY17 Earnings Guidance
www.americanbankingnews.com - December 7 at 5:08 PM
Edwards Lifesciences (EW) to Repurchase $1.00 billion in   SharesEdwards Lifesciences (EW) to Repurchase $1.00 billion in Shares
www.americanbankingnews.com - December 7 at 11:26 AM
Edwards Lifesciences Board Approves New $1 Billion Share Repurchase Program - PR Newswire (press release)Edwards Lifesciences' Board Approves New $1 Billion Share Repurchase Program - PR Newswire (press release)
www.prnewswire.com - December 7 at 10:04 AM
Edwards Lifesciences buys Harpoon Medical for $100M - Seeking AlphaEdwards Lifesciences buys Harpoon Medical for $100M - Seeking Alpha
seekingalpha.com - December 7 at 10:04 AM
Epidarex Capital Portfolio Company Harpoon Medical Acquired By Edwards LifesciencesEpidarex Capital Portfolio Company Harpoon Medical Acquired By Edwards Lifesciences
www.prnewswire.com - December 7 at 6:25 AM
Edwards Lifesciences Corporation (EW) to Post Q1 2019 Earnings of $1.10 Per Share, Leerink Swann ForecastsEdwards Lifesciences Corporation (EW) to Post Q1 2019 Earnings of $1.10 Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - December 6 at 9:38 PM
Edwards Acquires Harpoon MedicalEdwards Acquires Harpoon Medical
finance.yahoo.com - December 6 at 5:06 PM
Edwards Lifesciences Corporation Forecasted to Post Q1 2018 Earnings of $1.03 Per Share (EW)Edwards Lifesciences Corporation Forecasted to Post Q1 2018 Earnings of $1.03 Per Share (EW)
www.americanbankingnews.com - December 6 at 10:16 AM
ETFs with exposure to Edwards Lifesciences Corp. : December 5, 2017ETFs with exposure to Edwards Lifesciences Corp. : December 5, 2017
finance.yahoo.com - December 5 at 5:01 PM
Edwards Lifesciences (EW) Upgraded to Buy on Improving Sales GrowthEdwards Lifesciences (EW) Upgraded to Buy on Improving Sales Growth
investorplace.com - December 5 at 12:27 PM
Edwards Lifesciences Corporation (EW) Expected to Post FY2019 Earnings of $4.48 Per ShareEdwards Lifesciences Corporation (EW) Expected to Post FY2019 Earnings of $4.48 Per Share
www.americanbankingnews.com - December 2 at 10:00 AM
Edwards Lifesciences Earns RS Rating UpgradeEdwards Lifesciences Earns RS Rating Upgrade
finance.yahoo.com - December 1 at 5:06 PM
Edwards Lifesciences Corporation (EW) VP Sells $617,185.00 in StockEdwards Lifesciences Corporation (EW) VP Sells $617,185.00 in Stock
www.americanbankingnews.com - November 30 at 7:50 PM
Edwards Lifesciences (EW) "Buy" Rating Reiterated at Canaccord GenuityEdwards Lifesciences' (EW) "Buy" Rating Reiterated at Canaccord Genuity
www.americanbankingnews.com - November 30 at 12:32 AM
Implied Volatility Surging for Edwards Lifesciences (EW) Stock OptionsImplied Volatility Surging for Edwards Lifesciences (EW) Stock Options
finance.yahoo.com - November 29 at 9:55 AM
Analyzing Synergetics USA (SURG) and Edwards Lifesciences (EW)Analyzing Synergetics USA (SURG) and Edwards Lifesciences (EW)
www.americanbankingnews.com - November 28 at 7:10 PM
Recent EW NewsRecent EW News
www.bloomberg.com - November 28 at 5:00 PM
Edwards Lifesciences Pipeline Strong Amid Rising ExpensesEdwards Lifesciences' Pipeline Strong Amid Rising Expenses
www.zacks.com - November 28 at 8:56 AM
Edwards Lifesciences Corporation (EW) Expected to Post Quarterly Sales of $861.05 MillionEdwards Lifesciences Corporation (EW) Expected to Post Quarterly Sales of $861.05 Million
www.americanbankingnews.com - November 25 at 9:04 AM
ETFs with exposure to Edwards Lifesciences Corp. : November 24, 2017ETFs with exposure to Edwards Lifesciences Corp. : November 24, 2017
finance.yahoo.com - November 24 at 10:39 AM
Edwards Lifesciences Corp. breached its 50 day moving average in a Bullish Manner : EW-US : November 22, 2017Edwards Lifesciences Corp. breached its 50 day moving average in a Bullish Manner : EW-US : November 22, 2017
finance.yahoo.com - November 22 at 7:10 PM
Edwards Lifesciences Corporation (EW) CEO Sells $3,515,694.00 in StockEdwards Lifesciences Corporation (EW) CEO Sells $3,515,694.00 in Stock
www.americanbankingnews.com - November 22 at 4:21 AM
What Should You Know About Edwards Lifesciences Corporation’s (EW) Growth?What Should You Know About Edwards Lifesciences Corporation’s (EW) Growth?
finance.yahoo.com - November 17 at 10:18 PM
Edwards Lifesciences: Analyst Recommendations in NovemberEdwards Lifesciences: Analyst Recommendations in November
finance.yahoo.com - November 17 at 12:20 PM
Edwards Lifesciences: Expected to Report Robust Revenues in 2017Edwards Lifesciences: Expected to Report Robust Revenues in 2017
finance.yahoo.com - November 17 at 12:20 PM
Edwards Lifesciences: Small Rise in Net Profit Margins ExpectedEdwards Lifesciences: Small Rise in Net Profit Margins Expected
finance.yahoo.com - November 17 at 12:20 PM
Larry L. Wood Sells 18,960 Shares of Edwards Lifesciences Corporation (EW) StockLarry L. Wood Sells 18,960 Shares of Edwards Lifesciences Corporation (EW) Stock
www.americanbankingnews.com - November 16 at 7:50 PM
Edwards Lifesciences Corporation (EW) Receives Consensus Rating of "Buy" from AnalystsEdwards Lifesciences Corporation (EW) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - November 16 at 5:06 PM
Edwards Lifesciences Corporation (EW) Director Schack Wesley W. Von Sells 1,000 SharesEdwards Lifesciences Corporation (EW) Director Schack Wesley W. Von Sells 1,000 Shares
www.americanbankingnews.com - November 13 at 7:52 PM
ETFs with exposure to Edwards Lifesciences Corp. : November 13, 2017ETFs with exposure to Edwards Lifesciences Corp. : November 13, 2017
finance.yahoo.com - November 13 at 6:59 PM
Industry Group Rank Metrics Limit Edwards Lifesciences (EW) Ratings Upgrade to HoldIndustry Group Rank Metrics Limit Edwards Lifesciences (EW) Ratings Upgrade to Hold
investorplace.com - November 7 at 4:18 PM
Zacks: Brokerages Expect Edwards Lifesciences Corporation (EW) Will Post Quarterly Sales of $861.05 MillionZacks: Brokerages Expect Edwards Lifesciences Corporation (EW) Will Post Quarterly Sales of $861.05 Million
www.americanbankingnews.com - November 6 at 6:03 AM
$0.90 EPS Expected for Edwards Lifesciences Corporation (EW) This Quarter$0.90 EPS Expected for Edwards Lifesciences Corporation (EW) This Quarter
www.americanbankingnews.com - November 4 at 3:18 AM
ETFs with exposure to Edwards Lifesciences Corp. : November 2, 2017ETFs with exposure to Edwards Lifesciences Corp. : November 2, 2017
finance.yahoo.com - November 2 at 7:41 PM
Cramer's lightning round: I'm a buyer of Edwards Lifesciences despite the negativityCramer's lightning round: I'm a buyer of Edwards Lifesciences despite the negativity
finance.yahoo.com - November 1 at 7:33 PM

SEC Filings

Edwards Lifesciences (NYSE:EW) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Edwards Lifesciences (NYSE:EW) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Edwards Lifesciences (NYSE EW) Stock Chart for Friday, December, 15, 2017

Loading chart…

This page was last updated on 12/15/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.